Lung endothelial cell platelet-activating factor production and inflammatory cell adherence are increased in response to cigarette smoke component exposure

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 302, Issue 1, 2012, Pages

  Sharma, Janhavi ^a   Young, Dawn M ^a   Marentette, John O ^a   Rastogi, Prerna ^a   Turk, John ^b   McHowat, Jane ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cigarette smoke extract; Endothelium; Phospholipase A 2

Indexed keywords

[2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; ACETYL HYDROLASE; CIGARETTE SMOKE; GINKGOLIDE B; HYDROLASE; PHOSPHOLIPASE A2 GROUP IV; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ADHESION; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LUNG ENDOTHELIUM; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; CELL ADHESION; CELL LINE; ENDOTHELIAL CELLS; GROUP VI PHOSPHOLIPASES A2; HUMANS; INFLAMMATION; LUNG; MICE; MICE, KNOCKOUT; NEUTROPHILS; PHOSPHOLIPID ETHERS; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, G-PROTEIN-COUPLED; TOBACCO SMOKE POLLUTION;

EID: 83755173561     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00179.2011     Document Type: Article

References (57)

1. Adhikari B, Kahende J, Malarcher A, Pechacek T, Tong V. Smokingattributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep 57: 1226-1228, 2008.
2. Aldonyte R, Brantly M, Block E, Patel J, Zhang J. Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp Lung Res 35: 59-75, 2009.
3. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34: J258-J265, 2010.
4. Bao S, Miller DJ, Ma Z, Wohltmann M, Eng G, Ramanadham S, Moley K, Turk J. Male mice that do not express group VIA phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility. J Biol Chem 279: 38194-38200, 2004.
5. Barbieri SS, Zacchi E, Amadio P, Gianellini S, Mussoni L, Weksler BB, Tremoli E. Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res 90: 475-483, 2011.
6. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8: 183-192, 2008.
7. Berge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 21: 46S-53S, 2003.
8. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 89: 1117-1119, 2002.
9. Bielicki JK, Knoff LJ, Tribble DL, Forte TM. Relative sensitivities of plasma lecithin:cholesterol acyltransferase, platelet-activating factor acetylhydrolase, and paraoxonase to in vitro gas-phase cigarette smoke exposure. Atherosclerosis 155: 71-78, 2001.
10. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-7, 1959.
11. Bridges RB, Fu MC, Rehm SR. Increased neutrophil myeloperoxidase activity associated with cigarette smoking. Eur J Respir Dis 67: 84-93, 1985.
12. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50: S237-42, 2009.
13. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67: 1033-1036, 1991.
14. Camussi G, Tetta C, Baglioni C. The role of platelet-activating factor in inflammation. Clin Immunol Immunopathol 57: 331-338, 1990.
15. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 29: 1224-1238, 2007.
16. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 294: L612-L631, 2008.
17. Damico R, Simms T, Kim BS, Tekeste Z, Amankwan H, Damarla M, Hassoun PM. p53 mediates cigarette smoke-induced apoptosis of pulmonary endothelial cells: inhibitory effects of macrophage migration inhibitor factor. Am J Respir Cell Mol Biol 44: 323-332, 2011.
18. Doherty DE, Downey GP, Worthen GS, Haslett C, Henson PM. Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils. Lab Invest 59: 200-213, 1988.
19. Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor-α and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 45: 1223-1229, 2006.
20. Hagiwara E, Takahashi KI, Okubo T, Ohno S, Ueda A, Aoki A, Odagiri S, Ishigatsubo Y. Cigarette smoking depletes cells spontaneously secreting Th(1) cytokines in the human airway. Cytokine 14: 121-126, 2001.
21. Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J Biol Chem 283: 11097-11106, 2008.
22. Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645-2653, 2004.
23. Hsu CL, Wu YL, Tang GJ, Lee TS, Kou YR. Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: role of heme oxygenase-1. Pulm Pharmacol Ther 22: 286-296, 2009.
24. Imaizumi T. Intravascular release of platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking. In: Proceedings of the Third International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids. Tokyo: 1989, p78.
25. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 88: 3259-3287, 1996.
26. Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta 1761: 1359-1372, 2006.
27. Kell PJ, Creer M, Crown K, Wirsig K, McHowat J. Inhibition of platelet-activating factor (PAF) acetylhydrolases by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther 307: 1163-1170, 2003.
28. Kihara Y, Yanagida K, Masago K, Kita Y, Hishikawa D, Shindou H, Ishii S, Shimizu T. Platelet-activating factor production in the spinal cord of experimental allergic encephalomyelitis mice via the group IVA cytosolic phospholipase A2-lyso-PAFAT axis. J Immunol 181: 5008-5014, 2008.
29. Kuijpers TW, Hakkert BC, Hart MHL, Roos D. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8. J Cell Biol 117: 565-572, 1992.
30. Lehr HA, Weyrich AS, Saetzler RK, Jurek A, Arfors KE, Zimmerman GA, Prescott SM, McIntyre TM. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest 99: 2358-2364, 1997.
31. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678-689, 2007.
32. MacNee W. Oxidants and COPD. Curr Drug Targets Inflamm Allergy 4: 627-641, 2005.
33. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 50-60, 2005.
34. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 51: 1-16, 2002.
35. Mariolis P, Rock VJ, Asman K, Merritt R, Malarcher A, Husten C, Pechacek T. Tobacco use among adults-United States, 2005. MMWR Morb Mortal Wkly Rep 55: 1145-1148, 2006.
36. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 100, Suppl 11: S97-S103, 1997.
37. Meyer M, McHowat J. The role of platelet-activating factor in the adherence of circulating cells to the endothelium. In: Recent Research Developments in Physiology, edited by Pandalai SG. Tivandrum, India: Research Signpost, 2004, vol. 2, p. 129-147.
38. Miyaura S, Eguchi H, Johnston JM. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autocoid, platelet-activating factor. Circ Res 70: 341-347, 1992.
39. Muller WA. Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6: 323-344, 2011.
40. Nana-Sinkam SP, Lee JD, Sotto-Santiago S, Stearman RS, Keith RL, Choudhury Q, Cool C, Parr J, Moore MD, Bull TM, Voelkel NF, Geraci MW. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med 175: 676-685, 2007.
41. Pare PD, Wiggs BR, James A, Hogg JC, Bosken C. The comparative mechanics and morphology of airways in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 143: 1189-1193, 1991.
42. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 22: 727-733, 2002.
43. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci USA 81: 3534-3538, 1984.
44. Rastogi P, McHowat J. Inhibition of calcium independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium. Respir Physiol Neurobiol 165: 167-174, 2009.
45. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761: 1246-1259, 2006.
46. Sharma J, Turk J, McHowat J. Endothelial cell prostaglandin I2 and platelet-activating factor production are markedly attenuated in the calciumindependent phospholipase A2β knockout mouse. Biochemistry 49: 5473-5481, 2010.
47. Shindou H, Hishikawa D, Nakanishi H, Harayama T, Ishii S, Taguchi R, Shimizu T. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase. J Biol Chem 282: 6532-65399, 2007.
48. Smith MR, Kinmonth AL, Luben RN, Bingham S, Day NE, Wareham NJ, Welch A, Khaw KT. Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis 169: 331-337, 2003.
49. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2: 372-377, 2002.
50. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 23: 73-83, 2009.
51. Talukder MA, Johnson WM, Varadharaj S, Lian J, Kearns PN, El-Mahdy MA, Liu X, Zweier JL. Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. Am J Physiol Heart Circ Physiol 300: H388-H396, 2011.
52. Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther 23: 376-383, 2010.
53. Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 4: 607-618, 2005.
54. Tithof PK, Elgayyar M, Cho Y, Guan W, Fisher AB, Peters-Golden M. Polycyclic aromatic hydrocarbons present in cigarette smoke cause endothelial cell apoptosis by a phospholipase A2-dependent mechanism. FASEB J 16: 1463-1464, 2002.
55. Tjoelker LW, Stafforini DM. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 1488: 102-123, 2000.
56. White MC, McHowat J. Protease activation of calcium-independent phospholipase A2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res 120: 597-605, 2007.
57. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 48: 278-285, 2006.